Iovance Biotherapeutics’ US$211 Million Common Stock Offering

DLA Piper advised Iovance Biotherapeutics, Latham & Watkins advised the underwriters on the transaction.Iovance Biotherapeutics, Inc. (Iovance), a biotechnology company focused on innovating, developing and delivering…